These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

131 related items for PubMed ID: 2438777

  • 1. The m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma.
    Canellos GP, Skarin AT, Klatt MM, Rosenthal DS, Case DC, Pinkus GS, Jochelson MS, Yeap BY, Shipp MA.
    Semin Hematol; 1987 Apr; 24(2 Suppl 1):2-7. PubMed ID: 2438777
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. A phase III comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse non-Hodgkin's lymphomas.
    Guglielmi C, Gherlinzoni F, Amadori S, Mazza P, Mantovani L, Lauria F, Martelli M, Zinzani PL, Greco V, Poletti G.
    Haematologica; 1989 Apr; 74(6):563-9. PubMed ID: 2483401
    [Abstract] [Full Text] [Related]

  • 5. The m-BACOD combination chemotherapy regimen in large-cell lymphoma: analysis of the completed trial and comparison with the M-BACOD regimen.
    Shipp MA, Yeap BY, Harrington DP, Klatt MM, Pinkus GS, Jochelson MS, Rosenthal DS, Skarin AT, Canellos GP.
    J Clin Oncol; 1990 Jan; 8(1):84-93. PubMed ID: 1688615
    [Abstract] [Full Text] [Related]

  • 6. Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology.
    Canellos GP, Skarin AT, Rosenthal DS, Moloney WC, Frei E.
    Cancer Treat Rep; 1981 Jan; 65 Suppl 1():125-9. PubMed ID: 6173118
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [CHOP-bleo versus m-BACOD in the treatment of intermediate and high-grade malignant lymphomas].
    Avilés A, Huerta J, Guzmán R, Zepeda G, Díaz-Maqueo JC.
    Rev Invest Clin; 1990 Jan; 42(4):271-6. PubMed ID: 1708910
    [Abstract] [Full Text] [Related]

  • 11. Methotrexate-leucovorin factor rescue regimens in diffuse large cell lymphoma.
    Skarin AT, Canellos GP.
    NCI Monogr; 1987 Jan; (5):71-6. PubMed ID: 3501548
    [Abstract] [Full Text] [Related]

  • 12. Low dose methotrexate, bleomycin, doxorubicin, cyclophosphamide, vincristine, and dexamethasone with zalcitabine in patients with acquired immunodeficiency syndrome-related lymphoma. Effect on human immunodeficiency virus and serum interleukin-6 levels over time.
    Levine AM, Tulpule A, Espina B, Boswell W, Buckley J, Rasheed S, Stain S, Parker J, Nathwani B, Gill PS.
    Cancer; 1996 Aug 01; 78(3):517-26. PubMed ID: 8697399
    [Abstract] [Full Text] [Related]

  • 13. Diffuse large cell non-Hodgkin's lymphoma: results of M-BACOD combination chemotherapy.
    Polliack A, Uziely B, Isacson R, Lugassy G, Rochlemer S, Gez E, Libson E, Sulkes A, Weshler Z.
    Isr J Med Sci; 1988 Aug 01; 24(9-10):619-22. PubMed ID: 2462553
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B, Jancić-Nedeljkov R, Sretenović M, Milivojević G, Janković S, Petrović M.
    Srp Arh Celok Lek; 1998 Aug 01; 126(9-10):345-8. PubMed ID: 9863405
    [Abstract] [Full Text] [Related]

  • 15. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group.
    Kaplan LD, Straus DJ, Testa MA, Von Roenn J, Dezube BJ, Cooley TP, Herndier B, Northfelt DW, Huang J, Tulpule A, Levine AM.
    N Engl J Med; 1997 Jun 05; 336(23):1641-8. PubMed ID: 9171066
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. A variant of ProMACE-CytaBOM chemotherapy for non-Hodgkin's lymphoma with threefold higher drug dose size but identical cumulative dose intensity. A pilot study of the Italian lymphoma study group (GISL).
    Gobbi PG, Ghirardelli ML, Avanzini P, Baldini L, Quarta G, Stelitano C, Broglia C, Loni C, Silingardi V, Ascari E.
    Haematologica; 2000 Mar 05; 85(3):263-8. PubMed ID: 10702814
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.